Go-CHOP for newly diagnosed intestinal T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding the drug Go-CHOP to standard chemotherapy can help people newly diagnosed with intestinal T-cell lymphoma. It aims to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a new diagnosis of intestinal T-cell lymphoma that has not been treated yet.
- Your doctor expects you to live at least 12 more weeks.
- You must agree to use effective birth control during and for 6 months after treatment.
- You cannot have cancer that has spread to your brain or spinal cord, or have had a stem cell transplant.
- You cannot have active infections, certain heart problems, or recent use of other cancer treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding one of two experimental drugs to the standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma, a rare blood cancer. It aims to see if the combination is safe and effective.
This Phase 2 trial tests how well Go-CHOP works as the first treatment for peripheral T-cell lymphoma (PTCL) subtypes. It aims to see whether adding golidocitinib to standard chemotherapy can control the lymphoma and improve outcomes.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This trial tests a new oral medication called golidocitinib for people who have just been diagnosed with a specific type of T-cell lymphoma and have not had any prior treatment. The goal is to see if this JAK1 inhibitor can help control the disease.
This trial tests a new drug (tucidinostat) added to standard chemotherapy (CHOP) for people newly diagnosed with a specific type of lymphoma called PTCL-TFH. It aims to see if the combination works better than standard treatment alone.
This trial tests a combination of three drugs for people with peripheral T-cell lymphoma who cannot have intensive chemotherapy. The goal is to see if this treatment works and is safe.
Hear when a new Enteropathy Associated T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.